Defects of lipoprotein metabolism in familial combined hyperlipidaemia

Current Opinion in Lipidology

Volumn 9, Issue 3, 1998, Pages 189-196

  De Graaf, Jacqueline ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; FATTY ACID; LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; FAMILIAL HYPERLIPEMIA; GENETIC DISORDER; GENETIC HETEROGENEITY; GLUCONEOGENESIS; HEART INFARCTION; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; METABOLISM; PRIORITY JOURNAL; REVIEW;

ADIPOSE TISSUE; APOLIPOPROTEIN B-100; APOLIPOPROTEIN C-II; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INSULIN RESISTANCE; LIPOPROTEIN LIPASE; LIPOPROTEINS; LIPOPROTEINS, LDL;

EID: 0031799961     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199806000-00002     Document Type: Review

References (80)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52:1544-1568.
2. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987; 7:203-207.
3. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993; 13:427-434.
4. Hokanson JE, Krauss RM, Albers JJ, Austin MA, Brunzell JD. LDL physical and chemical properties in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15:452-459.
5. Bredie SJH, Kiemeney LA, de Haan AFJ, Demacker PNM, Stalenhoef AFH. Inherited susceptibility determines the distribution of dense low density lipoprotein subtraction profiles in familial combined hyperlipidemia. Am J Hum Genet 1996; 58:812-822. In this study the inheritance of small, dense LDL subfraction profiles, based on LDL particles density, was investigated in 40 well defined Dutch FCH families. A major autosomal locus recessively inherited, with a high population frequency, and an additional small polygenic component best explained the LDL subfraction distribution in these families.
6. Kwiterovich POJ. Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol 1993; 4:133-143.
7. Bredie SJH, Demacker PNM, Stalenhoef AFH. Metabolic and genetic aspects of familial combined hyperlipidemia with emphasis on LDL heterogeneity. Eur J Clin Invest 1997; 27:802-811.
8. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia. Eur J Clin Invest 1980; 10:17-22.
9. Kissebah AH, Alfarsi S, Evans DJ. Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis 1984; 4:614-624.
10. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993; 13:1110-1118.
11. Castro Cabezas M, de Bruin TWA, Jansen H, Kock LA, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 1993; 13:804-814.
12. Castro Cabezas M, Erkelens DW, Kock LAW, de Bruin TWA. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest 1994; 24:669-678.
13. Castro Cabezas M, de Bruin TWA, de Valk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993; 92:160-168.
14. Bredie SJH, Tack CJJ, Smits P, Stalenhoef AFH. Non-obese patients with familial combined hyperlipidemia are insulin resistant as compared with their non-affected relatives. Arterioscler Thromb Vasc Biol 1997; 17:1465-1471. A reduced insulin sensitivity was demonstrated by means of the euglycaemic clamp technique in male non-obese FCH patients as compared with their normolipidaemic relatives.
15. Aitman TJ, Godsland IF, Farren B, Crook D, Wong HJ, Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997; 17:748-754. Impaired insulin action in FCH patients was demonstrated, both on the suppression of nonesterified fatty acids and on stimulation of glucose disposal. A primary defect in fatty acid metabolism may contribute to the lipid abnormalities in this disorder.
16. Arner P. Is familial combined hyperlipidaemia a genetic disorder of adipose tissue. Curr Opin Lipidol 1997; 8:89-94. An excellent review on the putative role of adipose tissue in the pathogenesis of FCH. The adipose candidate genes, including those of LpL, HSL, acylation stimulatory protein and adrenergic receptors, are discussed.
17. Sniderman AD, Cianflone KM. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 1993; 13:629-636.
18. Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 1992; 12:1176-1183.
19. Patsch W, Sharrett AR, Chen IY, Lin-Lee YC, Brown SA, Gotto AM Jr, Boerwinkle E. Associations of allelic differences at the AI-CIII-AIV gene cluster with carotid artery intima-media thickness and plasma lipid transport in hypercholesterolemic-hypertriglyceridemic humans. Arterioscler Thromb 1994; 14:874-883.
20. Wojciechowski AP, Farrall M, Cullen P, Wilson TM, Bayliss JD, Farren B, et al. Familial combined hyperlipidemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24. Nature 1991; 349:161-164.
21. Ginsberg HN, Le NA, Goldberg Y, Gibson JC, Rubenslein A, Wang Juorson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78:1287-1295.
22. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implication for the pathophysiology of apoB production. J Lipid Res 1990; 30:567-582.
23. Cuchel M, Schaefer EJ, Millar JS, Jones PJH, Dolnikowski GG, Vergani C, Lichtenstein AH. Lovastatin decreases de novo cholesterol synthesis and LDL apoB-100 production rates in combined-hyperlipidemic males. Arterioscler Thromb Vasc Biol 1997; 17:1910-1917. This stable isotope kinetic study investigated the effect of lovastatin on apoB metabolism in male FCH patients. The decline in plasma lipid levels after treatment with lovastatin was attributable to reductions in the production rate and fractional synthesis rate of de-novo cholesterol synthesis and the production rate of apoB-100-containing lipoproteins. A comprehensive review on published data on variations in metabolism of apoB-containing lipoproteins is included.
24. Aguilar-Salinas CA, Barrett PHR, Kelber J, Delmez J, Schonfeld G. Physiologic mechanisms of action of lovastatin in nephrotic syndrome. J Lipid Res 1995; 36:188-199.
25. Aguilar-Salinas CA, Barrett PHR, Pulai J, Zhu XL, Schonfeld G. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler Thromb Vasc Biol 1997; 17:72-82.
26. Austin MA, Wijsman E, Guo SW, Krauss RM, Brunzell JD, Deeb S. Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia. Genet Epidemiol 1991; 8:287-297.
27. Rotter JI, Bu X, Cantor RM, Warden CH, Brown J, Gray RJ, et al. Multilocus genetic determinants of LDL particle size in coronary artery disease families. Am J Hum Genet 1996; 58:585-594.
28. Forster LF, Stewart G, Bedford DK, Stewart JP, Caslake MJ, Packard CJ, et al. Stable isotope turnover studies of apolipoprotein B in combined hyperlipidemia before and after treatment with atorvastatin, a new HMG-CoA reductase inhibitor [abstract]. Circulation 1996; 94:583.
29. Huff MW, Burnett JR. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol 1997; 8:138-145. An excellent review on the putative mechanisms whereby β-hydroxy-β-methyl-glutaryl coenzyme A reductase inhibitors lower the plasma concentrations of apoB-containing lipoproteins.
30. Conde K, Vergara-Jimenez M, Krause BR, Newton RS, Fernandez ML. Hypocholesterolemic actions of atorvastatin are associated with alterations in hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res 1996; 37:2372-2382.
31. Havel RJ, Goldstein JL, Brown MS. Lipoproteins and lipid transport. In: Bondy PK, Rosenberg LE (editors): Metabolic control and disease, 8th ed. Philadelphia: Saunders WB; 1980. pp. 393-494.
32. Stalenhoef AFH, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J Clin Invest 1986; 78:722-728.
33. Stalenhoef AFH, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. Proc Natl Acad Sci USA 1984; 81:1839-1843.
34. Seed M, Mailly F, Vallance D, Doherty E, Winder A, Talmud P, Humphries SE. Lipoprotein lipase activity in patients with combined hyperlipidaemia. Clin Invest 1994; 72:100-106.
35. Reymer PWA, Groenemeyer BE, Gagne E, Miao L, Appelman EEG, Seidel JC, et al. A frequently occuring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Hum Mol Genet 1995; 4:1543-1549.
36. De Bruin TWA, Mailly F, van Barlingen HHJJ, Fisher R, Castro Cabezas M, Talmud P, et al. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia. Eur J Clin Invest 1996; 26:631-639.
37. Hoffer MJV, Bredie SJH, Boomsma DI, Reymer PWA, Kastelein JJP, de Knijff P, et al. The lipoprotein lipase (Asn291 Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidemia. Atherosclerosis 1996; 119:159-167.
38. Pajukanta P, Porkka KVK, Antikainen M, Taskinen MR, Perola M, Murtomaki-Repo S, et al. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families. Arterioscler Thromb Vasc Biol 1997; 17:841-850.
39. Knudsen P, Murtomaki S, Antikainen M, Ehnholm S, Lahdenpera S, Ehnholm C, Taskinen MR. The Asn291 Ser and Ser 477stop mutations of the lipoprotein lipase gene and their significance for lipid metabolism in patients with hypertriglyceridaemia. Eur J Clin Invest 1997; 29:928-935.
40. Nevin DN, Brunzell JD, Deeb SS. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arterioscler Thromb 1994; 14:869-873.
41. Dallinga-Thie GM, Bu X, Van Linde Sibenius-Trip M, Rotter JI, Lusis AJ, de Bruin TWA. Apolipoprotein AI-CMI-AIV gene cluster in familial combined hyperlipidemia: effects of LDL-cholesterol and apolipoproteins B and CIII. J Lipid Res 1996; 37:136-147.
42. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23:97-105.
43. Swinkels DW, Demacker PNM, Hendriks JCM, van't Laar A. Low density lipoprotein subtractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis 1989; 9:604-613.
44. de Rijke YB, Bredie SJH, Demacker PNM, Vogelaar JM, Hak-Lemmers HLM, Stalenhoef AFH. The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification; studies on subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997; 17:127-133. Total LDL in FCH patients was less well protected against in-vitro oxidation than was total LDL from normolipidaemic relatives. In addition, the decreased redox status of coenzyme Q10 in LDL from individuals with FCH suggests that the LDL in the circulation is already modified because of lipid peroxidation.
45. de Graaf J, Hal-Lemmers HLM. Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11:298-306.
46. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34:295-308.
47. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willen WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917-1921.
48. Marzetta CA, Foster DM, Brunzell JD. Conversion of plasma VLDL and IDL precursors into various LDL subpopulations using density gradient ultracentrifugation. J Lipid Res 1990; 31:975-984.
49. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 1986; 77:663-672.
50. Fisher WR, Zech LA, Bardalaye P, Warmke G, Bierman M. The metabolism of apolipoprotein B in subjects with hypertriglyceridemia and polydisperse LDL. J Lipid Res 1980; 21:760-774.
51. Ginsberg HN, Ngai C, Wang XJ, Ramakrishnan R. Increased production rates of LDL are common in individuals with low plasma levels of HDL cholesterol, independent of plasma triglyceride concentrations. Arterioscler Thromb 1993; 13:842-851.
52. Packard CJ, Munro A, Lorimer AR, Gotto AM, Shepherd J. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest 1984; 74:2178-2192.
53. Krauss RM, Hellerstein MK, Neese RA, Blanche PJ, LaBelle MA, Shames DM. Altered metabolism of large very low density liporoteins in subjects with a predominance of small low dense lipoproteins [abstract]. Circulation 1995; 92:1102.
54. Tall AR. Plasma chotesteryl ester protein. J Lipid Res 1993; 34:1255-1271.
55. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effects of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993; 13:147-153.
56. Griffin BA, Packard CJ. Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 1994; 5:200-206.
57. Deckelbaum RJ, Eisenberg S, Oschry Y, Butbul E, Sharon I, Olivecrona T. Reversible modification of human plasma low density lipoproteins toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters. J Biol Chem 1982; 257:6509-6517.
58. Guerin M, Bruckert E, Dolphin PJ, Chapman MJ. Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia. Eur J Clin Invest 1996; 26:485-494.
59. Tato F, Vega GL, Tall AR, Grundy SM. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1991; 15:112-120.
60. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW, Marcel YL. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester protein activity and other lipoprotein variables. Arterioscler Thromb 1991; 11:797-804.
61. Austin MA, Brunzell JD, Fitch WL, Krauss RM. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990; 10:520-530.
62. Austin MA. Genetics of low-density lipoprotein subclasses. Curr Opin Lipidol 1993; 4:125-132.
63. Bredie SJH, de Bruin TWA, Demacker PNM, Kastelein JJP, Stalenhoef AFH. Comparison of gemfibrozil versus simvastatin in familial combined hyerlipidemia and effects on apolipoprotein-B-containing lipoproteins. low-density lipoprotein subfraction profile and low density-lipoprotein oxidizability. Am J Cardiol 1995; 75:348-353.
64. Bredie SJH, Vogelaar JM, Demacker PNM, Stalenhoef AFH. Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Atherosclerosis 1996; 126:312-324.
65. Cianflone K, Roncan DAK, Maslowska M, Saldo A, Forden J, Sniderman AD. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 1994; 33:9489-9495.
66. Cianflone KM, Maslowska MH, Sniderman AD. Impaired response of fibroblasts from patients with hyperapobetaliproproteinemia to acylation stimulating protein. J Clin Invest 1990; 85:722-730.
67. Stralfors P, Bjorgell P, Beifrage P. Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin. Proc Natl Acad Sci USA 1984; 81:3317-3321.
68. Reynisdottir S, Eriksson M, Angelin B, Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J Clin Invest 1995; 95:2161-2169.
69. Simsolo RB, Ong JM, Saffari B, Kern PA. Effects of improved diabetes control on the expression of lipoprotein lipase in human adipose tissue. J Lipid Res 1992; 33:1777-1784.
70. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993; 92:141-146.
71. Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP Jr, Mayer EJ, Krauss RM. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993; 88:381-387.
72. Ascaso JF, Sales J, Merchante A, Real J, Lorente R, Martinez-Valls J, Carmena R. Influence of obesity on plasma lipoproteins, glycaemia and insulinaemia in patients with familial combined hyperlipidaemia. Int J Obes 1997; 21:360-366.
73. Nuutila P, Koivisto VA, Ruotsalainen U, Teras M, Haaparanta M, Bergman J, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992; 89:1767-1774.
74. Lewis GE, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein in humans. J Clin Invest 1995; 95:158-166.
75. Gonzalez-Manchoon C, Martin-Requero A, Ayuso MS, Parrilla R. Role of endogenous fatty acids in the control of hepatic gluconeogenesis. Arch Biochem Biophys 1992; 292:95-101.
76. Pihlajamaki J, Rissanen J, Heikkinen S, Karjalainen L, Laakso M. Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997; 17:1039-1044.
77. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich POJ. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoprotein]. Proc Natl Acad Sci USA 1980; 77:604-608.
78. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.
79. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988; 259:3579-3586.
80. Hunt SC, Wu LL, Hopkins PN, Stults BM, Kuida H, Ramirez ME, et al. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis 1989; 9:335-344.